Gemini Bio Products, which manufactures cell culture products and custom cGMP bioprocess liquids, says it has secured financing from BroadOak Capital Partners. The transaction with BroadOak provides GeminiBio additional capital to expand its cGMP liquid manufacturing facility, according to GeminiBio.

GeminiBio’s new capacity will allow the company to better service customers requiring both small and large volume lots of critical cGMP process liquids, including medias, buffers, and other liquid solutions used in both upstream and downstream biomanufacturing, explains Jay Hertweck, GeminiBio executive VP and CCO.

“With the completion of the new large volume liquid manufacturing suites, GeminiBio will have market leading capabilities for biotech customers, including cell and gene therapy manufacturers, due to our ability to manufacture cGMP process liquids in lot sizes from 10 to 10,000 liters,” he continues. “GeminiBio’s liquid manufacturing capacity expansion project is expected to be completed by the second quarter of 2022.”

GeminiBio is a portfolio company of BelHealth Investment Partners, a healthcare private equity firm based in Fort Lauderdale.

Previous articleYokogawa Acquires Insilico Biotechnology
Next articleNeuro Drug Discovery Innovations: From Maps to Drugs